Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating hemophilia

C W Peterson

    American Pharmacy
    |August 1, 1994
    PubMed
    Summary
    This summary is machine-generated.

    Hemophilia A and B are inherited bleeding disorders. Effective management involves factor replacement therapy, individualized treatment plans, and proactive bleeding prevention for optimal patient well-being.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.

    Gene therapy·2013
    Same author

    3D solution structure of copper and silver-substituted yeast metallothioneins.

    FEBS letters·1996
    Same author

    Exploring psychiatric prescribing practices: the relationship between the role of the provider and the appropriateness of prescribing.

    General hospital psychiatry·1987
    Same author

    Venous thrombosis: an overview.

    Pharmacotherapy·1986
    Same author

    Theoretical framework for coronary care nursing education.

    The American journal of nursing·1978
    Same author

    Teaching and evaluating synthesis in an associate degree nursing program--a developmental experience.

    League exchange·1975

    Area of Science:

    • Hematology
    • Genetics

    Background:

    • Hemophilias A and B are inherited bleeding disorders due to deficiencies in clotting factors VIII or IX.
    • Patient well-being relies on preventing and treating hemorrhage, which can be spontaneous or trauma-induced.

    Purpose of the Study:

    • To outline the current understanding and management of hemophilia A and B.
    • To emphasize the importance of individualized therapeutic plans and factor replacement therapy.

    Main Methods:

    • Review of current literature on hemophilia management.
    • Discussion of factor replacement therapy, safety profiles, and challenges like inhibitors.

    Main Results:

    • Factor replacement therapy is the cornerstone of hemophilia treatment.

    Related Experiment Videos

  • Modern factor concentrates offer improved safety but can still have adverse effects.
  • Patients with inhibitors pose a significant management challenge.

    • Conclusions:

    • Individualized therapeutic plans are crucial for effective hemophilia management.
    • Pharmacists play a vital role in the pharmaceutical care of hemophilia patients.
    • Ongoing research and development are needed to address challenges like inhibitors.